New MRI techniques to check tumor response in pancreatic cancer
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
This tests whether adding high-resolution diffusion MRI and magnetic resonance elastography (MRE) can better show tumor response in adults with non-metastatic pancreatic adenocarcinoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy, France) |
| Trial ID | NCT06842303 on ClinicalTrials.gov |
What this trial studies
Adults with CT-diagnosed non-metastatic pancreatic adenocarcinoma will undergo MRI exams that include high-resolution diffusion sequences and magnetic resonance elastography. Images from these new sequences will be collected alongside routine imaging and clinical follow-up. Radiologic metrics from the advanced MRI sequences will be compared with standard imaging findings and patient outcomes to see if they provide clearer signs of tumor change. The protocol is performed at a single tertiary center and requires participants to be able to undergo MRI and provide informed consent.
Who should consider this trial
Good fit: Adults (≥18) with CT-confirmed non-metastatic pancreatic adenocarcinoma who can have MRI, are able to consent, and meet local social security requirements are eligible.
Not a fit: Patients with any contraindication to MRI, metastatic disease, inability to consent, pregnancy, minors, or those under certain legal restrictions are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the techniques could help doctors see tumor changes more clearly or earlier, which may improve treatment decisions for patients.
How similar studies have performed: Prior pilot work with high-resolution diffusion MRI and MRE has shown promising signals in pancreatic tumors, but these approaches remain exploratory and not yet standard of care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT; * Adult patient: age ≥ 18 years; * Patient affiliated with a social security system or beneficiary of such a system; * Patient who has received complete information about the research organization and has signed an informed consent form. Exclusion Criteria: * Patient with a contraindication to MRI. * Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code. * Pregnant woman, parturient, or breastfeeding mother; * Minor (non-emancipated) individual; * Adult individual under legal protection (guardianship, curatorship, or judicial safeguard); * Adult individual unable to express consent. * Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.
Where this trial is running
Vandœuvre-lès-Nancy, France
- CHRU Nancy — Vandœuvre-lès-Nancy, France, France (Recruiting)
Study contacts
- Study coordinator: Guillaume DROUOT, PhD
- Email: g.drouot@chru-nancy.fr
- Phone: 0385157666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.